Infinity Pharmaceuticals Inc. (INFI)

Oncology Corporate Profile

Stock Performance


HQ Location

780 Memorial Drive
Cambridge, MA 2139

Company Description

Infinity's objective is to discover, develop, and deliver patients best-in-class medicines for the treatment of cancer and related conditions. Infinity has built a pipeline of innovative product candidates for multiple cancer indications, all of which represent proprietary applications of their expertise in small molecule drug discovery and development.


This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
duvelisibHsp90 inhibitorChronic Lymphocytic Leukemia (CLL)III
duvelisibHsp90 inhibitorNon-Hodgkin's Lymphoma (NHL)II
duvelisibHsp90 inhibitorVarious cancer typesIAbbvie
IPI-549PI3K-gamma inhibitorVarious cancer typesI
IPI-549 (+ nivolumab)PI3K-gamma inhibitorVarious cancer typesI
IPI-443P13 kinase inhibitorVarious cancer typesPreclinical

View additional information on product candidates here »


Recent News Headlines

Infinity Regains Worldwide Rights To Duvelisib Following Mutual Agreement With AbbVie To End Collaboration

6/28/2016 05:37 pm

(Yahoo! Finance) June 28, 2016 - Infinity Pharmaceuticals, Inc. today announced that AbbVie Inc. has exercised its right to end its collaboration with Infinity to develop and commercialize duvelisib, an investigational, oral, dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma.

Infinity Reports Topline Results From DYNAMO™, A Phase 2 Monotherapy Study Of Investigational Molecule Duvelisib In Refractory Indolent Non-Hodgkin Lymphoma

6/14/2016 05:54 pm

(StreetInsider) June 14, 2016 - Infinity Pharmaceuticals, Inc. today announced that DYNAMO™, a registration-focused Phase 2 monotherapy study evaluating the efficacy and safety of duvelisib, an investigational, oral, dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, in patients with refractory indolent non-Hodgkin lymphoma (iNHL) met its primary endpoint of overall response rate.

Infinity Closes Research Ops as Blood Cancer Drug Comes Up Short

6/14/2016 02:30 pm

(Xconomy Boston) June 14, 2016 - Infinity Pharmaceuticals got a new lease on life in 2014 when pharma giant AbbVie plunked down $275 million to see if the company’s blood cancer drug, duvelisib, could stand out in a crowded field. The answer came back negative today, and Cambridge, MA-based Infinity has decided to gut its workforce as a result.

Infinity Announces Presentations On Investigational Development Candidates, Duvelisib And IPI-549, At Upcoming EHA And ASCO Meetings

5/20/2016 04:41 pm

(Yahoo! Finance) May 19, 2016 - Preliminary data from CONTEMPO, a phase 1b/2 combination study evaluating duvelisib in treatment-naïve patients with follicular lymphoma, to be presented at EHA.

How A Bad Night’s Sleep Might Worsen Cancer Development

3/14/2016 11:03 am

(EAU) Mar 12, 2016 – Recent studies have indicated that patients with sleep apnea may be associated with worse cancer outcomes. Now a new animal study, presented at the Annual Congress of the European Association of Urology in Munich, uncovers a possible mechanism which may underlie this link.

IBM's Cancer Moonshot: Using Computer Science To Battle Tumors

3/2/2016 12:01 pm

(Forbes) Mar 2, 2016 - Scientist Simone Bianco is leading a new effort at IBM aimed at using technology to scrutinize--and ultimately wipe out--cancer cells.

MDxHealth Announces Inclusion of ConfirmMDx in 2016 NCCN Guidelines for Prostate Cancer Early Detection

3/2/2016 12:00 pm

(TheStreet) Mar 2, 2016 - MDxHealth SA, today announced that its ConfirmMDx(R) for Prostate Cancer test has been included in the United States' 2016 National Comprehensive Cancer Network (NCCN) Guidelines.

New Biomarker Identifies Eye Cancer Patients at High Risk for Metastasis

3/1/2016 11:05 am

(University of Miami Health System) Mar 1, 2016 - A study by J. William Harbour, M.D., associate director for Basic Research and leader of the Eye Cancer Site Disease Group at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, and colleagues, published today in Clinical Cancer Research details the discovery of a biomarker that puts patients at a higher risk for metastasis of uveal melanoma.

NCCN Awarded $2 Million in Research Funding from Infinity Pharmaceuticals to Study Duvelisib in Hematologic Malignancies

2/9/2016 05:55 pm

(NCCN) Feb 9, 2016 - The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) has been awarded a $2-million grant from Infinity Pharmaceuticals, Inc. to evaluate the safety and effectiveness of duvelisib as a potential treatment for hematologic malignancies.

Medidata’s Risk-Based Monitoring Solution Selected by Infinity Pharmaceuticals to Advance Oncology Research

11/24/2015 05:47 pm

(Investor’s Business Daily) Nov 23, 2015 - Increased adoption of the Medidata Clinical Cloud® enables safer, faster and more insightful clinical trials.

UGA Researchers Discover Mechanism That Could Lead To Better Ovarian Cancer Treatment

10/27/2015 11:01 am

(University of Georgia/UGA Today) Oct 26, 2015 - Resistance to chemotherapy is a major problem for those suffering from ovarian cancer—a problem that prevents a cure from a disease dubbed the "silent killer.”

Sartans Improve Survival, Time To Recurrence In Liver Cancer

10/27/2015 11:01 am

(Physician’s Briefing/HealthDay News) Oct 26, 2015 — For patients with hepatocellular carcinoma after radiofrequency ablation, angiotensin II receptor 1 blockers (sartans) correlate with significantly improved overall survival and time to recurrence, according to a study published in the November issue of the Journal of Gastroenterology and Hepatology.

20% of Kids Don't Respond To Standard Cancer Treatment. Now There Is New Hope.

10/27/2015 11:01 am

(University of Montreal) Oct 26, 2015 - A new drug combination being trialled in a groundbreaking CHU Sainte-Justine/University of Montreal study is giving hope for survival, healing and improved quality of life to the 20% of children who do not respond to standard cancer treatments. Known as DEC-GEN, it's the world's first study involving children with solid tumors or recurrent or refractory leukemia.

Study: Sirolimus is Effective, Safe for Children and Young Adults with Treatment-Resistant Autoimmune Blood Conditions

10/27/2015 11:01 am

(ASH) Oct 26, 2015 - First prospective, multicenter trial evaluating safety and efficacy of sirolimus suggests drug could be an early therapy option for patients with autoimmune lymphoproliferative syndrome.

High-grade DCIS Detection Rates Increase in Older Women

10/27/2015 11:00 am

(RSNA) Oct 27, 2015 - The mammography detection rate of an early-stage but potentially invasive type of breast cancer rises with age, according to a large new study from Germany published online in the journal Radiology.

Are Black Men With Prostate Cancer Getting Inferior Care?

10/27/2015 11:00 am

(CBS News/HealthDay News) Oct 23, 2015 - Older black men with prostate cancer seem more likely to receive poorer quality of care that costs more compared to white men, a new study found.

Urinary Biomarkers Not Useful for Bladder Cancer Diagnosis

10/27/2015 11:00 am

(Medscape Medical News) Oct 26, 2015 - A meta-analysis of five urinary biomarkers found that they missed a significant proportion of patients with bladder cancer and were especially inaccurate in low-stage and low-grade tumors.

Chronic Constipation a Warning Sign for GI Disorders

10/27/2015 11:00 am

(Medscape Medical News) Oct 26, 2015 - Chronic constipation in adults could be a harbinger of more serious gastrointestinal (GI) disorders, including ischemic colitis, colorectal cancer, gastric cancer, and diverticulitis, according to a new study presented here at the American College of Gastroenterology 2015 Annual Meeting.

UEG Week: Improving Risk Profiling Is Key To Preventing Many GI Cancers

10/27/2015 11:00 am

(UEG) Oct 27, 2015 - Cancers of the gastrointestinal (GI) tract continue to exert their toll across Europe, with many diagnosed too late for effective treatment.

UEG Week: Increased Risk Of Large Bowel Cancer For Each 1 Cm Rise In Waist Circumference

10/27/2015 11:00 am

(UEG) Oct 26, 2015 - Experts speaking at the 23rd United European Gastroenterology Week (UEG Week 2015) in Barcelona, Spain today revealed compelling evidence of the link between excess body weight and risk of colorectal cancer (CRC).

Why Groundbreaking New Cancer Drugs Still Don’t Work For Most Patients

10/27/2015 10:05 am

(Washington Post/To Your Health) Oct 26, 2015 - New research published Monday in the journal Nature explores the molecular mechanisms that prevent immunotherapy drugs from working in some patients, and researchers hope the findings will help make the treatments more effective over time.

Genetic Testing Could Identify Men At A 10-Fold Increased Risk Of Testicular Cancer

10/27/2015 10:05 am

(ICR [UK]) Oct 27, 2015 - A new study of more than 25,000 men has uncovered four new genetic variants associated with increased risk of testicular cancer.

GW Pharmaceuticals and Otsuka Announce Results From Two Remaining Sativex(R) Phase 3 Cancer Pain Trials

10/27/2015 07:00 am

(Yahoo! Finance) Oct 27, 2015 - Consistent with the previously reported Phase 3 trial, Sativex did not meet the primary endpoint in these trials.

Amgen's Virus-based Cancer Treatment Awaits FDA's Final Word

10/27/2015 07:00 am

(RTT News) Oct 27, 2015 - After a not-so smooth sailing at panel review - though all but one of the 23 members voted in favor of approval - Amgen Inc.'s virus-based cancer treatment IMLYGIC for melanoma now awaits the FDA's final decision.

ASCO Calls for Comprehensive Payment Reform to Address Issue of Site Neutrality

10/27/2015 07:00 am

(ASCO in Action) Oct 26, 2015 - The American Society of Clinical Oncology (ASCO) called for comprehensive physician payment reform to support the full scope of services required by patients with cancer, rather than jeopardizing patient outcomes by reducing the available resources in a particular cancer care setting in an effort to achieve “site neutrality” in reimbursement for oncology services.

Infinity To Provide Update On Duvelisib And Immuno-Oncology Development Candidate IPI-549 During 2015 Research And Development Day

10/6/2015 03:15 pm

(TheStreet) Oct 6, 2015 - During today's presentations, Infinity will review its anticipated timelines for the development and commercialization of duvelisib.

Infinity Announces Enrollment Of 120th Patient In Phase 2 DYNAMO™ Study Evaluating Duvelisib In Indolent Non-Hodgkin Lymphoma

9/30/2015 04:41 pm

(Infinity) Sept 30, 2015 - Infinity Pharmaceuticals, Inc. today announced that the 120th patient has been enrolled in DYNAMO™, a Phase 2 study in patients with refractory indolent non-Hodgkin lymphoma (iNHL) evaluating the safety and efficacy of duvelisib, an oral, dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma.

Infinity Expands Pipeline with Addition of IPI-549, an Immuno-Oncology Development Candidate for the Treatment of Solid Tumors

9/18/2015 04:53 pm

(MarketWatch) Sept 18, 2015 - Infinity Pharmaceuticals, Inc. today announced the expansion of its pipeline with the addition of IPI-549, an orally administered immuno-oncology development candidate that selectively inhibits phosphoinositide-3-kinase gamma (PI3K-gamma), for the treatment of solid tumors.

PharmaMar Shows New Data for YONDELIS and PM1183 in Soft Tissue Sarcoma and Solid Tumors at ECC 2015

9/14/2015 11:01 am

(PharmaMar) Sept 14, 2015 - PharmaMar announces that it will show new data from clinical pivotal studies as well as real-life data from prospective non-interventional studies to highlight the role of YONDELIS® (trabectedin) in STS, during the 18th ECCO - 40th ESMO European Cancer Congress, Vienna, 25 - 29 September 2015 (ECC 2015).

Infinity Reports Phase 1 Data Showing Clinical Activity of Duvelisib in Treatment-Naïve Patients with Chronic Lymphocytic Leukemia

6/1/2015 12:06 am

(StreetInsider) May 31, 2015 - Infinity Pharmaceuticals, Inc. today announced new clinical data for duvelisib (IPI-145), an oral, dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma in patients with treatment-naïve chronic lymphocytic leukemia (CLL), a potentially fatal hematologic malignancy (blood cancer).

Infinity Announces New Data for Duvelisib to Be Presented at the 2015 American Society of Clinical Oncology Annual Meeting

5/14/2015 06:13 pm

(MarketWatch) May 13, 2015 - Infinity Pharmaceuticals, Inc. today announced the upcoming poster presentations of new clinical, translational and preclinical data with duvelisib (IPI-145), an oral, dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29-June 2 in Chicago, Il.

Statin Use Improves Renal Cell Cancer Survival

4/27/2015 10:05 am

(VICC) Apr 17, 2015 - A new study led by Vanderbilt University investigators found that patients being treated with statins at the time of surgery for kidney cancer, also known as renal cell carcinoma, had improved overall survival and disease-specific survival.

Infinity Reports Preclinical Data for Duvelisib in Combination with Venetoclax at the 2015 American Association for Cancer Research Annual Meeting

4/21/2015 05:17 pm

(MarketWatch) Apr 20, 2015 - Infinity Pharmaceuticals, Inc. today announced the presentation of new preclinical and translational data for duvelisib (IPI-145), an oral, dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, in combination with venetoclax (ABT-199), an investigational inhibitor of the BCL-2 protein, at the American Association for Cancer Research (AACR) Annual Meeting 2015 in Philadelphia, Pennsylvania.

Genmab Announces Preliminary Results in Phase II Study of Daratumumab in Double Refractory Multiple Myeloma

2/4/2015 11:03 am

(Genmab) Feb 3, 2015 — Genmab A/S announced today preliminary results from the Phase II study of daratumumab in double refractory multiple myeloma conducted by its collaboration partner Janssen Biotech, Inc.

Ahead of the Bell: Infinity Pharmaceuticals Shares Slide

1/8/2015 06:31 pm

(BloombergBusinessweek/Associated Press) Jan 8, 2015 - Infinity Pharmaceuticals will stop studying one of its potential drugs as a rheumatoid arthritis treatment after it failed to generate enough improvement in patients during a mid-stage study.

Infinity Reports New Translational Research and Updated Phase 1 Data of Investigational Oncology Compound Duvelisib at American Society of Hematology Annual Meeting

12/9/2014 10:34 pm

(TheStreet) Dec 9, 2014 - Updated data from phase 1 study show duvelisib activity as a monotherapy in relapsed/refractory Indolent Non-Hodgkin Lymphoma and relapsed/refractory T-Cell Lymphoma.

Merck Buys Rights to NewLink's Experimental Ebola Vaccine

11/24/2014 12:04 pm

(Reuters) Nov 24, 2014 - Merck & Co Inc will buy worldwide commercial rights to NewLink Genetics Corp's experimental Ebola vaccine.

Mayo Clinic Researchers: TNF Inhibitors May Increase Cancer Risk in the Eye

11/17/2014 05:01 am

(Mayo Clinic) Nov 13, 2014 - Mayo researchers studied three patients — two women and a man — who were treated for inflammatory disease and developed melanoma tumors in one eye within a year to two of taking TNF inhibitors.

Women Press FDA to Encourage Sexual Dysfunction Drugs

10/28/2014 07:05 am

(Wall Street Journal) Oct 27, 2014 - A series of women told an FDA workshop that they suffer from years of sexual dysfunction and that the agency should encourage companies to produce drugs to treat the condition.